financetom
Business
financetom
/
Business
/
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
Aug 25, 2025 11:17 AM

MannKind Corporation on Monday agreed to acquire scPharmaceuticals Inc. for a deal value of up to approximately $360 million, or $5.35 per share.

The deal marks MannKind’s strategic expansion into cardiorenal medicine, establishing its cardiometabolic business alongside its orphan lung division. It is also made possible on the heels of MannKind’s $500 million strategic financing agreement with Blackstone.

ScPharmaceuticals ( SCPH ) currently markets Furoscix, an FDA-approved on-body infuser delivering furosemide to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD).

The estimated total addressable market opportunity equates to more than $10 billion in the U.S. alone.

For the six months ended June 30, net sales totaled $27.8 million, up 96% year-over-year.

The Furoscix ReadyFlow Autoinjector is on track for a Q3 2025 supplemental New Drug Application (sNDA) submission. It aims to enable patients to reduce treatment time from five hours to less than 10 seconds.

“This acquisition expands our patient-centered brands and highlights MannKind’s dedication to delivering innovative therapies for cardiometabolic and orphan lung diseases,” said MannKind ( MNKD ) CEO Michael Castagna. “With multiple anticipated product launches and indication expansions, we expect to continue to diversify our revenue streams and accelerate our double-digit growth goals over the next decade.”

The combined company will own Afrezza, Furoscix, and V-Go. Combined with Tyvaso DPI-related revenues, these commercial products result in an annualized run rate of over $370 million, based on the second-quarter 2025 earnings.

Separately, MannKind ( MNKD ) is advancing a late-stage pipeline that includes:

Inhaled Clofazimine (MNKD-101), currently in a phase 3 global study for nontuberculous mycobacterial (NTM) lung disease

Nintedanib DPI (MNKD-201), expected to initiate a phase 2 clinical trial for IPF by year-end 2025.

Price Action: SCPH stock is up 15.36% at $5.59, and MNKD stock is down 4.50% at $3.93 at the last check on Monday. 

Read Next:

Bill Gates And Jeff Bezos Bet On Robots: FieldAI Hits $2 Billion Valuation After $405 Million Raise Backed By Nvidia

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Canadian Net REIT Announces the Sale of Five Gas Station Properties in Quebec
BRIEF-Canadian Net REIT Announces the Sale of Five Gas Station Properties in Quebec
Jul 17, 2024
July 17 (Reuters) - Canadian Net Real Estate Investment Trust: * CANADIAN NET REIT ANNOUNCES THE SALE OF FIVE GAS STATION PROPERTIES IN QUEBEC * CANADIAN NET REAL ESTATE INVESTMENT TRUST: TOTAL CONSIDERATION FROM THOSE SALES WAS APPROXIMATELY $12.8MLN Source text for Eikon: Further company coverage: ...
Correction: Prologis Q2 Core Funds From Operations, Revenue Falls; Updates 2024 Core FFO Outlook
Correction: Prologis Q2 Core Funds From Operations, Revenue Falls; Updates 2024 Core FFO Outlook
Jul 17, 2024
08:32 AM EDT, 07/17/2024 (MT Newswires) -- Prologis ( PLD ) reported Q2 core funds from operations Wednesday of $1.34 per diluted share, compared with $1.83 a year earlier. Analysts polled by Capital IQ expected $1.07. Total revenue for the quarter ended June 30 was $2.01 billion, down from about $2.45 billion a year earlier. Analysts surveyed by Capital IQ...
Cognizant, Victory Capital Enter Five-Year Partnership for Tech and Security Support
Cognizant, Victory Capital Enter Five-Year Partnership for Tech and Security Support
Jul 17, 2024
08:43 AM EDT, 07/17/2024 (MT Newswires) -- Cognizant Technology Solutions ( CTSH ) said Wednesday it has entered a five-year partnership with Victory Capital Holdings ( VCTR ) to provide technology infrastructure, security, and data analytics. The partnership will include managing infrastructure, security engineering, a 24/7 security operations center, and a service desk for monitoring and support, the company said....
Northern Trust's profit surges on fee income boost, accounting gain
Northern Trust's profit surges on fee income boost, accounting gain
Jul 17, 2024
(Reuters) - Asset and wealth manager Northern Trust ( NTRS ) posted a more than two-fold jump in second-quarter profit on Wednesday, thanks to higher fee income and an accounting gain of $878.4 million from a stock exchange deal with Visa. Hopes of a soft landing for the U.S. economy and investor frenzy around artificial intelligence have lifted the stock...
Copyright 2023-2025 - www.financetom.com All Rights Reserved